Daily Technical Summary Reports on Medical Supplies Stocks -- Ekso Bionics, Cooper Cos., TransEnterix, and OraSure Technologies
Aug 17, 2017, 06:25 ET
NEW YORK, August 17, 2017 /PRNewswire/ --
If you want a Stock Review on EKSO, COO, TRXC, or OSUR then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Today, DailyStockTracker.com covers the Medical Instruments and Supplies space, with focus on Ekso Bionics Holdings Inc. (NASDAQ: EKSO), The Cooper Cos. Inc. (NYSE: COO), TransEnterix Inc. (NYSE MKT: TRXC), and OraSure Technologies Inc. (NASDAQ: OSUR). According to an IBISWorld report, changing demographics, healthcare reform, and product innovation will shape the industry in the coming years. The aging population is expected to have the most significant effect on demand for medical supplies and instruments, as their need for care drives increases in overall public and private health expenditure. Register now and get full and free access to these DailyStockTracker.com research reports at:
Ekso Bionics Holdings
On Wednesday, shares in Richmond, California headquartered Ekso Bionics Holdings Inc. recorded a trading volume of 182,013 shares. The stock ended at $1.53, dropping 4.97% from the last trading session. The Company's shares are trading below their 50-day moving average by 18.42%. Furthermore, shares of Ekso Bionics, which designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets, have a Relative Strength Index (RSI) of 41.10.
On August 07th, 2017, Ekso Bionics reported financial results for the three months ended June 30th, 2017. Revenue for Q2 2017 was $1.9 million, gross profit was $0.4 million, and net loss was $5.5 million. Sales and marketing expenses for the quarter were $3.3 million, R&D expenses were $2.6 million and G&A expenses were $2.5 million. Access our complete research report on EKSO for free at:
Pleasanton, California headquartered The Cooper Cos. Inc.'s stock finished yesterday's session 0.68% higher at $244.57 with a total trading volume of 303,595 shares. The Company's shares have gained 16.79% over the previous three months and 39.81% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.24% and 20.21%, respectively. Furthermore, shares of Cooper Cos., which operates as a medical device company, have an RSI of 49.82.
On July 21st, 2017, research firm KeyBanc Capital Markets downgraded the Company's stock rating from 'Overweight' to 'Sector Weight'.
On August 09th, 2017, Cooper Cos. announced that Albert G. White III, Executive Vice President, CFO, and Chief Strategy Officer, will represent the Company at two upcoming financial conferences: the Baird 2017 Healthcare Conference on September 06th, 2017 at 12:15 p.m. ET in New York; and the Wells Fargo Securities 2017 Healthcare Conference on September 07th, 2017 at 8:50 a.m. ET in Boston, Massachusetts. The complimentary research report on COO can be downloaded at:
At the close of trading on Wednesday, shares in Morrisville, North Carolina headquartered TransEnterix Inc. rose 0.29%, ending the day at $0.68. The stock recorded a trading volume of 349,114 shares. The Company's shares have advanced 26.79% in the previous three months. The stock is trading 3.41% above its 50-day moving average. Moreover, shares of TransEnterix, which focuses on the development and commercialization of surgical robotic systems, have an RSI of 48.18.
On August 03rd, 2017, TransEnterix announced that it has installed a Senhance Surgical Robot at the Institute for Surgical Advancement at Florida Hospital Orlando. The Senhance Robot is placed under a collaboration agreement with Florida Hospital ISA. Nicholson Center Orlando will be used as a facility to perform pre-clinical training and procedural development in cooperation with surgical staff from Florida Hospital. Register for free on DailyStockTracker.com and get access to the latest report on TRXC at:
Bethlehem, Pennsylvania-based OraSure Technologies Inc.'s shares ended the day 1.17% lower at $20.29 with a total trading volume of 553,010 shares. The stock has gained 9.14% in the last month, 39.93% over the previous three months, and 131.09% on an YTD basis. The Company's shares are trading 14.54% above their 50-day moving average and 61.90% above their 200-day moving average. Additionally, shares of OraSure Technologies, which together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices, have an RSI of 61.11.
On July 24th, 2017, OraSure Technologies announced that its OraQuick® HIV Self-Test (HIVST) has been selected by UNITAID and Population Services International for use in Phase II of the HIV Self-Testing Africa (STAR) Project. The STAR Project Phase II, beginning in Q4 of 2017, will deploy HIV Self-Testing in Malawi, Zambia, Zimbabwe, South Africa, and additional African countries to demonstrate the population-level health impact of HIVST over a two-year period. Download your free research report on OSUR at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Share this article